Trials / Recruiting
RecruitingNCT06859788
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Sound Pharmaceuticals, Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ebselen | Glutathione peroxidase mimetic |
Timeline
- Start date
- 2025-10-29
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2025-03-05
- Last updated
- 2025-12-26
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06859788. Inclusion in this directory is not an endorsement.